PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20002083-4	2009	WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	70-73	paraoxonase 1	Homo sapiens	93-98	
20002083-4	2009	WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	136-139	paraoxonase 1	Homo sapiens	93-98	
20002083-4	2009	WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	136-139	paraoxonase 1	Homo sapiens	238-243	
20002083-10	2009	The influence of treatment with EFV, HDL-c and CD4 cell count on PON-1 activity was analysed.	efavirenz	32-35	paraoxonase 1	Homo sapiens	65-70	
20002083-13	2009	CONCLUSIONS: EFV-based antiretroviral regimens are associated with HDL particles with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	13-16	paraoxonase 1	Homo sapiens	136-141